A prospective, open-label, phase II, multi-center study of the safety, tolerability and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted (CAIV-T) in healthy children, aged 6 to 17 years.
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2009
At a glance
- Drugs Influenza virus vaccine live (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors MedImmune
- 31 Oct 2006 Status change
- 14 Dec 2005 New trial record.